CareDx CEO says focus on improving long-term outcomes
In an exclusive interview with The Fly, CareDx (CDNA) CEO Peter Maag talked about the molecular diagnostics company's future: "I think the one area where CareDx is probably going to in the future is the longitudinal data management, with the focus on improving long-term outcomes in patients. Maybe today people see us as a diagnostic company, but going forward it will be very important for us to allow individual and personalized medicine to this very high-cost, high-value patient population. Nobody else cares for the long-term outcome in these patients. The U.S. Healthcare system focuses very much on procedures, where we as a company try to bring this long-term view to patient outcomes." "Meet the Company" is The Fly's recurring series of exclusive short interviews with Executive Officers to offer a deeper look inside the company.